Axsome Therapeutics Q3 EPS $(1.32) Misses $(1.19) Estimate, Sales $57.79M Beat $55.75M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics reported Q3 losses of $(1.32) per share, missing the analyst consensus estimate of $(1.19) by 10.92 percent. This is a 23.36 percent decrease over losses from the same period last year. However, the company reported quarterly sales of $57.79 million, beating the analyst consensus estimate of $55.75 million by 3.67 percent, a 243.07 percent increase over sales from the same period last year.
November 06, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axsome Therapeutics reported a larger than expected loss for Q3, but beat sales estimates. This mixed result could lead to uncertainty in the market.
Axsome Therapeutics reported a larger than expected loss for Q3, which is a negative signal for investors. However, the company beat sales estimates, which is a positive signal. The mixed results could lead to uncertainty in the market, making it difficult to predict the short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100